PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Sprout Social(US:SPT) Businesswire·2026-03-26 02:04文章核心观点 - PureTech Health旗下实体公司Seaport Therapeutics在《科学·转化医学》期刊上发表了关于其候选药物GlyphAllo (SPT-300)的研究论文 [1] 公司动态 - Seaport Therapeutics是PureTech Health的创立实体 [1] - 公司宣布了其候选药物GlyphAllo (SPT-300)的学术发表 [1]